271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04795141 (ClinicalTrials.gov) | August 24, 2021 | 3/3/2021 | ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: ABY-035;Drug: Normal saline | Inmagene Biopharmaceuticals | Affibody | Terminated | 18 Years | N/A | All | 25 | Phase 2 | United States;China;Korea, Republic of;Cayman Islands |